Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics is benefiting from a major de-risking shift as Medicare has started paying for EsoGuard at its full expected rate of $1,938 per test, far above Q2’26 realized ASPs of about $530, which could materially lift revenue per test and improve collections. The first LBM coverage policy from Concert, alongside positive discussions with commercial payors and health systems, provides third-party validation that the test is medically necessary and could unlock broader reimbursement and adoption across a large, underpenetrated GERD population at risk for esophageal adenocarcinoma. Its fundamentals are further supported by a stronger balance sheet from the $15 million financing, a differentiated non-invasive product in EsoGuard/EsoCheck, and favorable guideline support that strengthens the case for scaling sales and utilization.

Lucid Diagnostics is viewed negatively because its commercial rollout remains early, revenue is still modest, and the company faces elevated denial rates from commercial payors despite Medicare reimbursement of $1,938 per test. Its own estimates were cut to $6.1 million for 2026 and $23 million for 2027, underscoring a slower-than-expected volume ramp and limited operating history in scaling EsoGuard/EsoCheck. The outlook is also constrained by balance sheet and liquidity risk, intellectual property and manufacturing risks, clinical utility study uncertainty, and intensifying competition, all of which could delay broader payer traction and commercial adoption.